title: Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate.
abstract: Ethnic differences in drug disposition may potentially influence therapeutic response to dabigatran, a reversible direct thrombin inhibitor used for the prevention and/or treatment of various thromboembolic disorders. This analysis of data from 18 clinical studies in healthy volunteers and patients with non-valvular atrial fibrillation (AF) or undergoing knee or hip arthroplasty investigated whether there were any clinically relevant differences in the pharmacokinetics and pharmacodynamics of dabigatran, the active form of dabigatran etexilate, between Japanese and Caucasian subjects. In pooled data from 14 phase I trials, total exposure (i.e. area under the plasma concentration-time curve [AUC]) after administration of dabigatran 150 mg once or twice-daily was on average 20% higher in Japanese than Caucasian subjects (median [10th to 90th percentile] 1,110 [644-1,824] vs. 924 [420-1,654] ng·h/ml) although the difference between the groups was not significant. Within-trial comparisons in subjects treated with dabigatran 150 mg twice-daily showed that AUC and maximum plasma concentration differed by less than 10% between the two groups. In patients with AF, trough concentrations after administration of 150 mg twice-daily were similar in Japanese and Caucasian subjects (80.1 [34.5-193.8] vs. 71.0 [34.0-190] ng/ml). Various factors, including body weight and renal clearance, may explain these observed pharmacokinetic differences. The relationship between plasma concentration and coagulation markers was similar and indicative of no difference in the exposure-pharmacodynamic response between these two groups. In conclusion, the results of this analysis show that the pharmacokinetics and pharmacodynamics of dabigatran are similar in Japanese and Caucasian subjects and suggest that there is no need for dose adjustment of dabigatran in Japanese subjects.
authors.affiliation: Translational Medicine, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany. sebastian.haertter@boehringer-ingelheim.com
authors.forename: Sebastian
authors.initials: S
authors.lastname: Härtter
authors.forename: Norio
authors.initials: N
authors.lastname: Yamamura
authors.forename: Joachim
authors.initials: J
authors.lastname: Stangier
authors.forename: Paul A
authors.initials: PA
authors.lastname: Reilly
authors.forename: Andreas
authors.initials: A
authors.lastname: Clemens
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019644:Arthroplasty, Replacement, Hip; D019645:Arthroplasty, Replacement, Knee; D044466:Asian People; D001281:Atrial Fibrillation / Q000097:blood / Q000188:drug therapy*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000069604:Dabigatran; D005260:Female; D006801:Humans; D008297:Male; D011183:Postoperative Complications; D011725:Pyridines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D044465:White People
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D011725:Pyridines; D000069604:Dabigatran